1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 1997
---------------
NEOTHERAPEUTICS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-28782 93-0979187
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
157 Technology Drive, Irvine, California 92618
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (714) 788-6700
--------------
Not Applicable
----------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Exhibit Index on Page 3
2
ITEM 5. OTHER EVENTS
On July 29, 1997, NeoTherapeutics, Inc. (the "Company") issued a Press
Release which reports additional interim results of the Canadian Phase I/II
trial of the Company's AIT-082 compound in Alzheimer's disease patients. A copy
of the Press Release is filed with this Report as Exhibit 99.1.
ITEM 7. EXHIBITS
Exhibits:
---------
99.1 Press Release dated July 29, 1997.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NEOTHERAPEUTICS, INC.
Date: July 29, 1997 By: /s/ SAMUEL GULKO
------------------------------------
Samuel Gulko
Chief Financial Officer
2
3
EXHIBIT INDEX
Exhibits Description
- -------- -----------
99.1 Press Release dated July 29, 1997.
3